{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:55:06Z","timestamp":1793318106846,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eprac.2024.09.016","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T21:01:57Z","timestamp":1738530117000},"page":"236-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Shailendra B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Wyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Afreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Maria","family":"Belalcazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-9052","authenticated-orcid":false,"given":"Melanie D.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Marrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Chiung-Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu Priya","family":"Pulipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihail","family":"Zilbermint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare","year":"2024","journal-title":"Glob Heart"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tcm.2019.09.005","article-title":"US trends in premature heart disease mortality over the past 50 years: Where do we go from here?","volume":"30","author":"Ritchey","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib6","article-title":"US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018","volume":"12","author":"Gao","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.016_bib7","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib8","article-title":"Bridging the racial disparity gap in lipid-lowering therapy","volume":"10","author":"Kalra","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jacl.2021.08.001","article-title":"Race\/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction","volume":"15","author":"Colvin","year":"2021","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.eprac.2024.09.016_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1002466","article-title":"Dyslipidemia among patients with type 2 diabetes in Jordan: Prevalence, pattern, and associated factors","volume":"10","author":"Hyassat","year":"2022","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/diaspect.21.3.177","article-title":"Best practices for lowering the risk of cardiovascular disease in diabetes","volume":"21","author":"Triplitt","year":"2008","journal-title":"Diabetes Spectrum"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.2022.10951","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: U.S. Preventive Services Task Force recommendation statement","volume":"328","year":"2022","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2024.09.016_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Associate of\u00a0Clincial Endocrinologists and American College of Endocrinology guideilnes for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.016_bib14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.016_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"24","key":"10.1016\/j.eprac.2024.09.016_bib16","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of\u00a0blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.016_bib17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.eprac.2024.09.016_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the\u00a0management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eprac.2023.01.012","article-title":"Protocol for development of American Association of Clinical Endocrinology clinical practice guidelines and consensus statements: summary of methodology, process, and policy - 2023 update","volume":"29","author":"Correa","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2024.09.016_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c3920","article-title":"Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review","volume":"341","author":"Cordoba","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.2018.4242","article-title":"Nontraditional risk factors in cardiovascular disease risk assessment","volume":"320","author":"Lin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2024.09.016_bib23","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2024.09.016_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2024.09.016_bib25","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7652","key":"10.1016\/j.eprac.2024.09.016_bib27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2024.09.016_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib29","article-title":"Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC\/AHA multisociety cholesterol treatment guidelines over the pooled cohort equation: insights from 3 large prospective cohorts","volume":"10","author":"Akintoye","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamainternmed.2022.1262","article-title":"Evaluation of the incremental value of a coronary artery calcium score beyond traditional cardiovascular risk assessment: a systematic review and meta-analysis","volume":"182","author":"Bell","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eprac.2024.09.016_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117217","article-title":"Lipoprotein(a) and the pooled cohort\u00a0equations for ASCVD risk prediction: the Multi-Ethnic Study of Atherosclerosis","volume":"381","author":"Bhatia","year":"2023","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.eprac.2024.09.016_bib32","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.eprac.2024.09.016_bib33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eprac.2024.09.016_bib34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.10.058","article-title":"Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment","volume":"67","author":"Yeboah","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25_suppl_2","key":"10.1016\/j.eprac.2024.09.016_bib36","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.eprac.2024.09.016_bib38","doi-asserted-by":"crossref","first-page":"np1","DOI":"10.1177\/2047487316653709","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju041","article-title":"Net risk reclassification p values: valid or misleading?","volume":"106","author":"Pepe","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib40","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222343","article-title":"Net reclassification index statistics do not help assess new risk models","volume":"306","author":"Kerr","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.eprac.2024.09.016_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jclinepi.2019.09.016","article-title":"Validation of clinical prediction models: what does the \u201ccalibration slope\u201d really measure?","volume":"118","author":"Stevens","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jama.2018.8359","article-title":"Risk assessment for cardiovascular disease with nontraditional risk factors: U.S. Preventive Services Task Force recommendation statement","volume":"320","year":"2018","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.eprac.2024.09.016_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/2047487317717346","article-title":"Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors","volume":"24","author":"Pe\u0107in","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45050","article-title":"Guiding principles to address the impact of algorithm bias on racial and ethnic disparities in health and health care","volume":"6","author":"Chin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.eprac.2024.09.016_bib45","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2024.09.016_bib47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","article-title":"Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations","volume":"184","author":"Anderson","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.09.016_bib48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.eprac.2024.09.016_bib49","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinternmed.2009.162","article-title":"Coronary artery calcification screening: estimated radiation dose and cancer risk","volume":"169","author":"Kim","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.015712","article-title":"Differences and disparities among self-referred and physician-referred populations undergoing coronary artery calcium scanning","volume":"17","author":"Marzlin","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.eprac.2024.09.016_bib51","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2019","journal-title":"Eur Heart J"},{"issue":"9965","key":"10.1016\/j.eprac.2024.09.016_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.eprac.2024.09.016_bib53","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2024.09.016_bib54","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2024.09.016_bib55","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.016_bib57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical\u00a0trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"issue":"15","key":"10.1016\/j.eprac.2024.09.016_bib60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in\u00a0patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2024.09.016_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2023.04.020","article-title":"The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with\u00a0peripheral arterial disease and intermittent claudication (Evol-PAD study)","volume":"55","author":"Clavijo","year":"2023","journal-title":"Cardiovasc Revasc Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.09.016_bib62","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","article-title":"Efficacy and safety of long-term evolocumab use among asian subjects - a subgroup analysis of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial","volume":"85","author":"Keech","year":"2021","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.016_bib63","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvaa024","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis","volume":"7","author":"Guedeney","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib65","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/clc.23448","article-title":"Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation","volume":"43","author":"Jackson","year":"2020","journal-title":"Clin Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2024.09.016_bib66","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2337\/dc15-0016","article-title":"Prevalence of and racial disparities in risk factor control in older adults with diabetes: the Atherosclerosis Risk in Communities Study","volume":"38","author":"Parrinello","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.016_bib67","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jama.2009.1227","article-title":"Sex differences in mortality following acute coronary syndromes","volume":"302","author":"Berger","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11936-020-00869-z","article-title":"Disparities in cardiovascular care and outcomes for women from racial\/ethnic minority backgrounds","volume":"22","author":"Balla","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.eprac.2024.09.016_bib69","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"16","key":"10.1016\/j.eprac.2024.09.016_bib70","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2024.09.016_bib71","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2024.09.016_bib72","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.09.016_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib75","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.eprac.2024.09.016_bib76","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib77","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.eprac.2024.09.016_bib78","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.eprac.2024.09.016_bib79","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.09.016_bib80","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib81","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jacl.2023.10.011","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","volume":"18","author":"Bays","year":"2024","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.eprac.2024.09.016_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2024.09.016_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9567","key":"10.1016\/j.eprac.2024.09.016_bib86","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.016_bib87","first-page":"537","article-title":"A\u00a0randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.eprac.2024.09.016_bib88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"228","author":"Nosaka","year":"2017","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib90","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/07853890600852880","article-title":"Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double-blind pilot study in primary prevention","volume":"38","author":"Baldassarre","year":"2006","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0049-3848(95)93837-P","article-title":"Effect of long-term, moderate-dose supplementation with omega-3 fatty acids on monocyte procoagulant activity and release of interleukin-6 in patients with coronary artery disease","volume":"77","author":"Eritsland","year":"1995","journal-title":"Thromb Res"},{"issue":"18","key":"10.1016\/j.eprac.2024.09.016_bib92","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.105.549527","article-title":"Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake","volume":"112","author":"Leaf","year":"2005","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.eprac.2024.09.016_bib96","first-page":"S99","article-title":"The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications","volume":"36","author":"von Schacky","year":"2001","journal-title":"Lipids"},{"issue":"14","key":"10.1016\/j.eprac.2024.09.016_bib94","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jacc.2014.07.956","article-title":"Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress","volume":"64","author":"Nigam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib95","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ajcn\/74.1.50","article-title":"Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol","volume":"74","author":"Nilsen","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"22","key":"10.1016\/j.eprac.2024.09.016_bib93","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib97","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2224","article-title":"Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis","volume":"2","author":"D\u2019Andrea","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib98","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.eprac.2024.09.016_bib99","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.eprac.2024.09.016_bib100","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib101","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2013.09.034","article-title":"The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)","volume":"231","author":"Brunner","year":"2013","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib102","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.016_bib103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/000331979504600401","article-title":"Effect of lipid-lowering treatment on progression of atherosclerotic lesions--a duplex ultrasonographic investigation","volume":"46","author":"Caruzzo","year":"1995","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.016_bib104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.eprac.2024.09.016_bib105","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"issue":"8931","key":"10.1016\/j.eprac.2024.09.016_bib106","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(94)90506-1","article-title":"Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group","volume":"344","author":"Sacks","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.09.016_bib107","first-page":"405","article-title":"The US Veterans Administration cardiology drug-lipid study: an interim report","volume":"Vol 4","author":"Schoch","year":"1969"},{"issue":"22","key":"10.1016\/j.eprac.2024.09.016_bib108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/heartjnl-2013-303926","article-title":"MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study","volume":"99","author":"Sibley","year":"2013","journal-title":"Heart"},{"issue":"23","key":"10.1016\/j.eprac.2024.09.016_bib109","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.eprac.2024.09.016_bib110","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A\u00a0randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.eprac.2024.09.016_bib112","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.clinthera.2019.06.012","article-title":"Serious adverse effects of extended-release niacin\/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial","volume":"41","author":"Haynes","year":"2019","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.016_bib113","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"2015","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2047487318816495","article-title":"Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: a systematic review and meta-analysis","volume":"26","author":"Riaz","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"21","key":"10.1016\/j.eprac.2024.09.016_bib115","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A\u00a0comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2024.09.016_bib118","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurjpc\/zwaa093","article-title":"Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis","volume":"28","author":"Khan","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.016_bib119","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.eprac.2024.09.016_bib120","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.016_bib121","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement","volume":"328","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib122","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"25","key":"10.1016\/j.eprac.2024.09.016_bib123","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl_1","key":"10.1016\/j.eprac.2024.09.016_bib124","article-title":"Abstract 12904: assessing low-density lipoprotein cholesterol risk in secondary prevention patients within the PINNACLE National Outpatient Registry","volume":"140","author":"Allen","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.eprac.2024.09.016_bib125","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.eprac.2024.09.016_bib126","first-page":"1","article-title":"Deaths: leading causes for 2019","volume":"70","author":"Heron","year":"2021","journal-title":"Natl Vital Stat Rep"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.016_bib127","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.016_bib128","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.016_bib129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/met.2014.0114","article-title":"Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus","volume":"13","author":"Ciriacks","year":"2015","journal-title":"Metab\u00a0Syndr Relat Disord"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:45:12Z","timestamp":1740627912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1530891X24006918"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}